Access cutting-edge hereditary malignant neoplasm treatment through this clinical trial at a research site in Ann Arbor. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Ann Arbor location
Preparing your pre-screening questions…
Access hereditary malignant neoplasm specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related hereditary malignant neoplasm treatment provided free
Check if you qualify for this hereditary malignant neoplasm clinical trial in Ann Arbor, MI
No-Cost Study Care
Local to Ann Arbor
Convenient for MI residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This clinical trial tests whether various web-based tools can help improve communication about hereditary cancer risk in families and decrease barriers to genetic testing for relatives of patients with hereditary cancer syndromes. Between 5% and 10% of all cancers are caused by genetic changes that are hereditary, which means that they run in families. Some kinds of cancer or certain cancers diagnosed in biological relatives may mean patients are more likely to have a genetic change. Once a genetic change is identified in a family, other biological relatives can choose to undergo testing themselves to better understand their cancer risk. The uptake of genetic testing in other biological relatives once a genetic condition is identified is about 20% to 30%. The Cascade Genetic Testing Platform is a virtual tool that seeks to overcome barriers related to logistics of family communication and improve dissemination of genetic testing information which is clinically actionable for individuals at highest risk for cancer. Using the Cascade Genetic Testing Platform may improve ways to share information about hereditary risk with biological relatives.
Sponsor: University of Michigan Rogel Cancer Center
Yes, this clinical trial (NCT06927947) has an active research site in Ann Arbor, MI that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for hereditary malignant neoplasm treatment options in Ann Arbor, MI, this clinical trial (NCT06927947) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Ann Arbor research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hereditary malignant neoplasm specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all hereditary malignant neoplasm clinical trials near you to find additional studies recruiting in your area.
See all ankylosing spondylitis clinical trials recruiting in Ann Arbor — not just this study.
Browse Ankylosing Spondylitis Trials in Ann Arbor →